Researchers Develop Nasal Drops to Combat Deadly Brain Cancer
A groundbreaking new development in the fight against glioblastoma, the deadliest form of brain cancer, has emerged as researchers at Washington University have successfully created nasal drops that can travel along the nerves of the nose into the central nervous system to target and fight these aggressive tumors.
Initial tests on mice have shown promising results, with the medication safely reaching its intended destination and providing protection against what is typically a fatal diagnosis.
Neurosurgeon Alexander Stegh, who led the study, expressed optimism about the potential of this noninvasive treatment approach, stating that it could pave the way for safer and more effective therapies for glioblastoma and other immune treatment-resistant cancers.
Traditionally, glioblastoma tumors have been challenging to treat due to their highly aggressive nature, late detection, and ability to evade the body’s immune response. These tumors also pose a challenge in terms of accessibility, as they often form in the brain or along the delicate central nervous system.
Previous research had focused on stimulating interferon genes in cancer cells to alert the immune system to the presence of the tumor. However, the drugs used for this purpose were not able to effectively reach the tumor site and required invasive administrations.
To address this issue, the team at Washington University developed a novel approach using nanotechnology to deliver drugs directly to the tumor via nasal drops. By encapsulating STING-activating molecules in spherical genetic material wrapped around a gold nanoparticle core, the researchers were able to achieve targeted delivery and activation of the immune response against the tumor.
In mouse models of glioblastoma, the gold-mounted genetic instructions successfully activated the STING pathway, resulting in inhibition of tumor growth. When combined with other immune-boosting drugs, the nasal drops were able to induce long-term immunity against glioblastoma.
While the researchers acknowledge that there is still a long road ahead before human clinical trials can begin, they are hopeful that this innovative approach could revolutionize the treatment of glioblastoma and other similar cancers.
Glioblastoma remains a significant health challenge, with only a small percentage of patients surviving beyond five years post-diagnosis. The development of noninvasive treatments like nasal drops could potentially improve outcomes for these patients and offer new hope in the battle against this devastating disease.
This groundbreaking research was recently published in the prestigious journal PNAS, marking a significant milestone in the quest for more effective treatments for glioblastoma.
